YahooAugust 20, 2026 at 9:21 AM NY15 days ago
Regeneron to challenge Ipsen as FDA clears bone disease drug
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Yahoo4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill44 minutes ago
Sector Update: Financial
Yahoo2 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo2 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill2 hours ago